ADMA
ADMA BIOLOGICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$11.07
+3.65%Year over year
Reported trailing growth
- Revenue
- +8.0%
- EBITDA
- +42.8%
- EBIT
- +39.1%
- EPS
- -17.2%
- Free cash flow
- +77.1%
- Operating cash flow
- +78.2%
Forward estimates
Based on analyst estimates
- Revenue
- +16.3%
- EBITDA
- +12.5%
- EPS
- +14.4%
Three-year CAGR
- Revenue
- +49.0%
- EBITDA
- +521.7%
- EBIT
- +197.5%
- Net income
- -25.7%
- EPS
- -27.1%
- Free cash flow
- +169.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026